Back to Authors

Stone, Jennifer D.

0000-0001-5654-5825

Mayo Clinic

AbbVie (United States)

Citations 1

Breaking tolerance with engineered class I antigen-presenting molecules
Parks, Christopher A. , Henning, Kalli R., Hansen, Michael J. , Keulen, Virginia P. Van , Reed, Brendan , Schrum, Adam G. , Gil, Diana , Kranz, David M. , Bordner, Andrew J., Barry, Michael A. , Pease, Larry R. , Pavelko, Kevin D. , Reed, Brendan K, Schrum, Adam G , Barry, Michael A , Stone, Jennifer D.

Proceedings of the National Academy of Sciences | April 1, 2019 | Volume: 116 | Issue: 8 | Pages: 3136-3145

10.1073/pnas.1807465116 Get It

Significance Provision of sufficient activating signals can drive self-tolerant T cells to cross-react on self-peptide-MHC in a breakdown of tolerance. This approach has been applied in the development of heteroclitic peptide vaccines, which retain sufficient similarity to self to allow reactivation of effector cells on unaltered self-epitopes but require detailed knowledge about the behavior of individual altered self-peptide antigens. We designed altered-self MHC mutant antigen-presenting molecules to drive CTL capable of cross-reacting on self-peptide-MHC and demonstrate the breaking of self-tolerance to defined and undefined self-antigens. These findings bear particular importance in the field of cancer immunotherapy in which breaking tolerance to weakly antigenic cancer-associated antigens is fundamental to vaccination strategies.